news

CUPERTINO, Calif., Dec. 23 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX), an emerging specialty pharmaceutical systems company, announced today the initiation of Phase III clinical testing for Remoxy(TM), a novel long-acting, abuse-deterrent oral formulation of oxycodone based on DURECT’s ORADUR(TM) technology licensed to Pain Therapeutics, Inc. On June 29, 2004, Pain Therapeutics announced the results of […]

CUPERTINO, Calif., Dec. 20 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX), an emerging specialty pharmaceutical systems company, and Voyager Pharmaceutical Corporation, a privately held specialty pharmaceutical company focused on diseases of aging, announced today the acceptance of the Investigational New Drug Application (“IND”) and clinical protocol by the FDA for a DURIN(TM)-based leuprolide acetate treatment of

CUPERTINO, Calif., Nov 22, 2004 /PRNewswire-FirstCall via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the Lazard First Annual Life Sciences Conference. The conference is being held at Mandarin Oriental Hotel in New York, New York. Dr. Felix Theeuwes, Chairman and Chief Scientific Officer, will be presenting at the conference

CUPERTINO, Calif., Nov 4, 2004 (PRNewswire-FirstCall via COMTEX) — DURECT Corporation announced today that it will present at the Fifteenth Annual CIBC Healthcare Conference. The conference is being held at The Plaza Hotel in New York, New York. Dr. James E. Brown, President and Chief Executive Officer, will be presenting at the conference on Tuesday,

CUPERTINO, Calif., Oct. 25 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended September 30, 2004 and an update on its development programs. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) Our net loss for the three months ended September 30, 2004 was $7.3 million or 14 cents per share, compared to $6.4 million

CUPERTINO, Calif., Oct. 25 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today the initiation of a Phase II clinical study for its post-operative pain relief depot (SABER-bupivacaine), a sustained-release formulation of a local anesthetic using the Company’s SABER(TM) drug delivery system. SABER-bupivacaine is designed to be administered, via injection, around an incision site following surgery

Patch to be Highlighted at ASA 2004 Annual Meeting CUPERTINO, Calif., Oct. 22 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) today announced the initiation of a phase I clinical trial for a new proprietary transdermal sufentanil product. The trial consists of a pharmacokinetic study in normal, healthy volunteers in Europe. The objectives of the clinical study

CUPERTINO, Calif., Oct 22, 2004 /PRNewswire-FirstCall via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the C. E. Unterberg, Towbin Specialty Pharmaceutical Conference. The conference is being held at The Palace Hotel in New York, NY. Dr. James E. Brown, President and Chief Executive Officer, will be presenting at the

CUPERTINO, Calif., Oct. 21 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the Rodman & Renshaw Techvest 6th Annual Healthcare Conference. The conference is being held at The Waldorf Astoria in New York, NY. Dr. James E. Brown, President and Chief Executive Officer, will be presenting at the conference on

CUPERTINO, Calif., Oct. 18 /PRNewswire-FirstCall/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) third quarter 2004 financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Monday, October 25, 2004 at 4:30 p.m. EDT with Jim Brown, President and Chief Executive Officer, Tom